Mount Sinai researchers present results at American Society of Hematology Meeting

December 07, 2015

Icahn School of Medicine at Mount Sinai researchers will present several landmark studies at the 2015 American Society of Hematology (ASH) meeting December 5-8, 2015, in Orlando, including data analysis of newly diagnosed multiple myeloma that revealed insight into key biological processes and deeper understanding of cellular systems and disease mechanisms, and two combination therapy strategies that showed high response rates in patients with difficult-to-treat myeloma.

Highlights of Mount Sinai research at ASH:

Towards a Network-Based Molecular Taxonomy of Newly Diagnosed Multiple Myeloma

Mount Sinai researchers, led by Samir Parekh, MBBS, constructed the first network biology of multiple myeloma based on RNA-sequencing data provided by the Multiple Myeloma Research Foundation (MMRF) and integrated cell mutations data to infer a better model and understanding of newly diagnosed multiple myeloma (MM). Their analysis revealed both known and unknown molecular features yielding valuable insight into key biological processes.

"We created a network model for MM and uncovered agreements between expressed genes and their molecular traits, and incorporating cell mutation data," said Dr. Parekh, Associate Professor of Hematology and Medical Oncology at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. "This unveiled significant associations between mutations, certain fundamental biological processes such as DNA repair and cell cycle, and identified key driver genes that will guide treatment and inform us of best therapies."

Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma

Daratumumab in combination with Pomalyst-dexamethasone and other traditional therapies has been shown to be safe and effective for patients with relapsed and/or refractory MM. "Our goal was to test the safety and tolerability of this combination," said Ajai Chari, MD, Associate Professor of Hematology and Medical Oncology and Director of Clinical Research in the Multiple Myeloma Program at TCI. "Patients had deep and durable response in a quick period of time, and the combination was well tolerated and did not result in any additional toxicity."

Combination Treatment of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib and Carfilzomib in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Initial Results from a Multicenter Phase 1/2b Study

Recent advances have improved outcomes for patients with multiple myeloma (MM); however, better therapies targeting new pathways are still needed. A multi-center research team evaluated 40 patients with MM who had received Ibrutinib (IBR), a once-daily Bruton's tyrosine kinase inhibitor that prevents both activation and signaling of B-cells, and observed that when combined with weekly dexamethasone yielded promising clinical potential and well tolerated by patients.

"The initial data has shown promising potential for this combination," said Dr. Chari. "Patients tolerated this combination and we believe it may positively regulate the myeloma stem cell-like population."
About the Mount Sinai Health System

The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services--from community-based facilities to tertiary and quaternary care.

The System includes approximately 6,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is ranked as one of the nation's top 10 hospitals in Geriatrics, Cardiology/Heart Surgery, and Gastroenterology, and is in the top 25 in five other specialties in the 2014-2015 "Best Hospitals" issue of U.S. News & World Report. Mount Sinai's Kravis Children's Hospital also is ranked in seven out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology, while Mount Sinai Beth Israel is ranked regionally.

For more information, visit or find Mount Sinai on Facebook, Twitter and YouTube.

The Mount Sinai Hospital / Mount Sinai School of Medicine

Related Multiple Myeloma Articles from Brightsurf:

Penn Study supports use of radiation before CAR therapy for multiple myeloma
Administering radiation therapy to multiple myeloma patients waiting for CAR T cells to be manufactured was found to be safe and undisruptive to CAR T therapy.

New multiple myeloma therapy shows promise in preclinical study
A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of The Journal of Nuclear Medicine.

A safer cell therapy harnesses patient T cells to fight multiple myeloma
A treatment for multiple myeloma that harnesses the body's cancer-fighting T cells was safe in humans and showed preliminary signs of effectiveness, according to a clinical trial involving 23 patients with relapsed or treatment-resistant disease.

Colorado tool, My-DST, may pick best multiple myeloma treatment
Response of liquid biopsies to approved drugs can help show resistance, predict response.

Case study: Treating COVID-19 in a patient with multiple myeloma
A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers.

New drug could reverse treatment resistance in advanced multiple myeloma
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease -- a point when many patients currently run out of options.

Single gene cluster loss may contribute to initiation/progression of multiple myeloma
The loss of one copy of the miR15a/miR16-1 gene cluster promoted initiation and progression of multiple myeloma in mice.

New CAR-T target yields promising results for multiple myeloma
In research published today in the journal Nature Communications, Utah-based scientists describe a novel way to treat cancers using chimeric antigen receptor (CAR) T cell therapy.

BCMA-targeted immunotherapy can lead to durable responses in multiple myeloma
An experimental, off-the-shelf immunotherapy that combines a targeted antibody and chemotherapy can lead to potentially durable responses in multiple myeloma patients whose disease has relapsed or is resistant to other standard therapies.

Study finds racial disparities in treatment of multiple myeloma patients
Among patients with multiple myeloma, African-Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances.

Read More: Multiple Myeloma News and Multiple Myeloma Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to